Bernd JahrsdĶrfer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9852397/publications.pdf Version: 2024-02-01



REDNO LAHDSOÃ DEED

#	Article	IF	CITATIONS
1	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell, 2021, 184, 2384-2393.e12.	28.9	848
2	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. Science Immunology, 2021, 6, eabj1031.	11.9	223
3	Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. Journal of Clinical Investigation, 2021, 131, .	8.2	212
4	Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants. EBioMedicine, 2022, 75, 103761.	6.1	104
5	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2021, 32, 3027-3033.	6.1	82
6	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination–specific humoral and cellular immunity in kidney transplant recipients. JCI Insight, 2022, 7, .	5.0	62
7	CD4+ T Cell–Derived IL-21 and Deprivation of CD40 Signaling Favor the In Vivo Development of Granzyme B–Expressing Regulatory B Cells in HIV Patients. Journal of Immunology, 2015, 194, 3768-3777.	0.8	57
8	B Cell Numbers Predict Humoral and Cellular Response Upon <scp>SARS</scp> – <scp>CoV</scp> â€2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	5.6	55
9	Robust and durable serological response following pediatric SARS-CoV-2 infection. Nature Communications, 2022, 13, 128.	12.8	54
10	Independent Side-by-Side Validation and Comparison of 4 Serological Platforms for SARS-CoV-2 Antibody Testing. Journal of Infectious Diseases, 2021, 223, 796-801.	4.0	51
11	mRNA Vaccines Enhance Neutralizing Immunity against SARS-CoV-2 Variants in Convalescent and ChAdOx1-Primed Subjects. Vaccines, 2021, 9, 918.	4.4	40
12	S100A4 and Uric Acid Promote Mesenchymal Stromal Cell Induction of IL-10+/IDO+ Lymphocytes. Journal of Immunology, 2014, 192, 6102-6110.	0.8	35
13	An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection. Antiviral Research, 2020, 181, 104882.	4.1	34
14	Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19–Convalescent Donors. Journal of Immunology, 2021, 206, 2614-2622.	0.8	22
15	Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies. Transfusion Medicine and Hemotherapy, 2021, 48, 137-147.	1.6	21
16	ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase. Immunity, Inflammation and Disease, 2018, 6, 448-455.	2.7	11
17	BNT162b2 Vaccination Elicits Strong Serological Immune Responses Against SARS-CoV-2 Including Variants of Concern in Elderly Convalescents. Frontiers in Immunology, 2021, 12, 743422.	4.8	10
18	Hepcidin/Ferritin Quotient Helps to Predict Spontaneous Recovery from Iron Loss following Blood Donation. Transfusion Medicine and Hemotherapy, 2015, 42, 390-395.	1.6	7

#	Article	IF	CITATIONS
19	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. Frontiers in Immunology, 2022, 13, 822885.	4.8	7
20	Erytra blood group analyser and kode technology testing of SARSâ€CoVâ€2 antibodies among convalescent patients and vaccinated individuals. EJHaem, 2022, 3, 72-79.	1.0	4
21	BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages. Frontiers in Immunology, 0, 13, .	4.8	4
22	Differential expression of serpins may selectively licence distinct granzyme B functions including antigen cross-presentation. Molecular Immunology, 2017, 87, 325-326.	2.2	1
23	CD27+IgD– B cells in the peripheral blood of colorectal cancer patients: on anti-tumor or tumor-protective mission?. Oncoscience, 2014, 1, 558-559.	2.2	0